Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Sep 092014
 

The Hygiology Post ®  has been presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 do appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.

Senesco Technologies today had the following article posted on their website titled “Senesco Announces Corporate Rebranding to Sevion Therapeutics” (https://www.senesco.com/news.php; obtained on 9-9-2014 and https://www.irdirect.net/pr/release/id/790200; obtained on 9-9-2014). The article began the following way:

“Senesco Technologies, Inc. (OTCQB:SNTI) (the ‘Company’ or ‘Sevion’), a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc.The Company will continue to trade as SNTI until a new ticker symbol is obtained.The rebranding and new corporate identity are first steps in fulfilling the Company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.

‘Sevion brings together several cutting-edge platform technologies. Novel antibody discovery systems and scaffolds address important therapeutic targets previously inaccessible with biologics, including GPCRs and ion channels, and nucleic acid-loaded nanoparticles leverage our deep understanding of the eIF5A ‘apoptosis gene’,’ said Ronald Martell, chief executive officer. ‘This new corporate identity will allow us to build broader awareness of our innovative platforms and objectives to advance a high-value pipeline of proprietary and partnered product candidates.’ ”

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2014                                    The Hygiology Post ®